Concord Biotech Limited (CONCORDBIO) — Cash Flow Quality Index
Concord Biotech Limited (CONCORDBIO) has a Cash Flow Quality Index of 0.67x as of March 2025. Operating cash flow of Rs2.47 Billion is below net income of Rs3.72 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Concord Biotech Limited debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Concord Biotech Limited Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for Concord Biotech Limited across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Concord Biotech Limited cash conversion from operations.
Annual Cash Flow Quality Index for Concord Biotech Limited (2020–2025)
Year-by-year earnings quality comparison for Concord Biotech Limited.
| Year | Quality Index | Operating CF (INR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | Rs2.47 Billion | Rs3.72 Billion | ▼ -22.7% |
| 2024 | 0.86x | Rs2.65 Billion | Rs3.08 Billion | ▼ -15.9% |
| 2023 | 1.02x | Rs2.46 Billion | Rs2.40 Billion | ▼ -13.6% |
| 2022 | 1.19x | Rs2.07 Billion | Rs1.75 Billion | ▲ +67.0% |
| 2021 | 0.71x | Rs1.67 Billion | Rs2.35 Billion | ▼ -22.4% |
| 2020 | 0.92x | Rs1.55 Billion | Rs1.69 Billion | — |